A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: Monotherapy with Nivolumab 360 mg, every 3 weeks intravenous administration Primary outcome(s): Objective response rate (ORR) determined by RECIST v1.1 Study Design: Single arm Non-randomized
创建时间：
2018-09-15
